-Reuters
Stifel Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $36
Stifel analyst Bradley Canino maintains ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and lowers the price target from $60 to $36.
Related Posts
Cannabis Conviction Is A Modern Day Scarlet Letter, Activist Weldon Angelos Says At Senate Hearing
Criminal reform and cannabis advocate Weldon Angelos, who launched The Cannabis Freedom Alliance with billionaire Charles Koch last year, told U.S.
BEST Q2 EPS $(0.54) Up From $(0.85) YoY, Sales $287.60M Miss $403.27M Estimate
BEST (NYSE:BEST) reported quarterly losses of $(0.54) per share. This is a 36.47 percent increase over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $287.60 million
